Embecta Corp. reported strong Q3 financial results with revenues of $295.5 million, up 8.4%. The company’s U.S. revenues increased by 11.6%, while international revenues increased by 5.0%. Operating income and margin also saw significant growth compared to the prior year period.

For the nine months ended June 30, 2025, Embecta Corp. reported revenues of $816.4 million, down 2.5%. The decrease was driven by unfavorable changes in volume and foreign currency impact. However, adjusted net income and earnings per diluted share increased compared to the prior year period.

Strategic highlights for Embecta Corp. include completing the global transition to their ERP system, advancing the brand transition program, and signing contracts with pharmaceutical companies. The company also substantially completed its restructuring plan and reduced debt during the fiscal year.

Embecta Corp. updated its fiscal year 2025 financial guidance, tightening and raising key metrics. The company now expects adjusted constant currency revenue growth of -3.6% to -3.0%, adjusted gross margin of 63.25% to 63.50%, and adjusted earnings per diluted share of $2.90 to $2.95.

As of June 30, 2025, Embecta Corp. had approximately $233.6 million in cash and equivalents, $1.489 billion of debt principal outstanding, and no amount drawn on its $500 million Revolving Credit Facility. The company also declared a quarterly cash dividend of $0.15 per share.

Embecta Corp. will host a conference call at 8:00 a.m. ET on August 8, 2025, to discuss its Q3 results. The call will be available via webcast on the company’s website. A webcast replay will be available after the call.

Embecta is a global company focused on insulin delivery and medical supplies. With approximately 2,000 employees worldwide, the company aims to improve lives through innovative solutions and partnerships. For more information, visit their website or follow them on social media channels.

Read more at GlobeNewswire: Embecta Corp. Reports Third Quarter Fiscal 2025 Financial